Company intelligence / Profile preview

Daré Bioscience, Inc.

San Diego, California, United Statesdarebioscience.gcs-web.com ↗

Ownership: Public · DARE
Development stage: Commercial

Overview

Daré has one FDA-approved product (XACIATO) for bacterial vaginosis. Other products are in various stages of development, with Sildenafil Cream 3.6% facing FDA delays for Phase 3 trials, leading the company to pursue a compounded version for market in Q4 2025.

Therapeutic areas: Women's HealthInfectious Diseases
Modalities: Topical creamsvaginal gelsintravaginal ringsimplants
Industry: Biotech

Drug pipeline

21 assets

DARE-BV1

Approved

20 more assets in the full pipeline.

Request access →

Partnerships

Organon (global license agreement for XACIATO)Bayer (licensed Ovaprene)Theramex (co-development and licensing agreement for Casea S)

Beyond the preview

Go deeper on Daré Bioscience, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Daré Bioscience, Inc..

Explore the full profile